Conmed vs LivaNova
CNMD and LIVN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNMD and LIVN compare
LivaNova is the larger company, worth 3.5 times as much as Conmed ($5.1B against $1.4B).
On earnings, Conmed is cheaper: it trades at 20.0× trailing earnings, against 27.1× for LivaNova.
LivaNova grew revenue faster over the last twelve months (12.4% versus 1.6% for Conmed).
LivaNova keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 5.4% at Conmed.
Conmed scores higher on the StockData Score (14 against 13 for LivaNova), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNMD | LIVN |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $5.1B |
| Share price | $48.39 | $91.92 |
| Change, 1 year | 15.1% | 66.0% |
| Change, 5 years | −64.2% | 10.3% |
| Beta (5Y) | 0.38 | 0.83 |
| Employees | 3,900 | 3,300 |
| StockData Score | ||
| Total score | 14 (better) | 13 |
| Valuation score | 6 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 4 | 4 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 20.0× (better) | 27.1× |
| P/S | 1.1× (better) | 3.4× |
| P/B | 1.4× (better) | 3.8× |
| EV/EBITDA | 16.3× (better) | 25.8× |
| P/FCF | 10.9× (better) | 34.1× |
| FCF yield | 9.2% (better) | 2.9% |
| Fair value | $67.87 | $69.65 |
| Margin of safety | 28.7% (better) | −32.0% |
| Growth | ||
| Revenue growth (TTM) | 1.6% | 12.4% (better) |
| Revenue growth, 5Y average | 9.8% (better) | 8.2% |
| Net income growth (TTM) | 14.6% | – |
| EPS growth (TTM) | 18.0% | – |
| EPS growth, 5Y average | 36.4% | – |
| Profitability | ||
| Gross margin | 57.6% | 68.1% (better) |
| Operating margin | 9.9% | 12.7% (better) |
| Net margin | 5.4% | 12.8% (better) |
| FCF margin | 9.7% | 10.1% (better) |
| Return on equity | 7.1% | 15.4% (better) |
| Return on invested capital | 5.2% | 18.2% (better) |
| Financial health | ||
| Debt / equity | 0.77 | 0.22 (better) |
| Net debt / EBITDA | 5.66 (better) | −1.19 |
| Interest coverage | 4.1× | 5.0× (better) |
| Current ratio | 1.49 (better) | 1.45 |
| Altman Z-score | 1.99 | 2.71 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Payout ratio | 8.4% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −5.6% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 114% | 108% |
| Held by insiders | 0.47% | 0.48% |
| Insider net buying, 12 months | $0 (better) | −$1.3M |
| Short interest, % of float | 6.3% | 11.6% |
Go deeper
- CNMD stock overview
- CNMD income statement
- CNMD valuation and score
- LIVN stock overview
- LIVN income statement
- LIVN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.